<DOC>
	<DOCNO>NCT02062554</DOCNO>
	<brief_summary>BHS cohort study consecutive myocardial infarction ( MI ) patient admit within first 24 hour symptom ongoing since May 2006 . The purpose study ass possible marker increase risk MI .</brief_summary>
	<brief_title>Brasilia Heart Study</brief_title>
	<detailed_description>In-hospital assessment Patients admit study submit in-hospital evaluation blood sample collection upon admission ( D1 ) fifth day ( D5 ) MI . Patients treat accord current US guideline STEMI assistant physicians responsible medical decision without influence investigator . Plasma DNA sample aliquoted storage -80 °C . DNA extract use QIAamp DNA Blood Mini Kit ( Quiagen , GmBH Hilden ) . Follow-up After hospital discharge , patient refer guideline-driven medical therapy study outpatient clinic reevaluate visit every three month . Lifestyle counsel diet , smoke cessation , regular physical activity weight loss orient patient . Follow-up prescription include simvastatin addition ezetimibe necessary ( LDL-C goal 70 mg/dL ) , captopril losartan hypertension reduce ejection fraction ( &lt; 40 % ) ; hypoglycemic treatment achieve HbA1c goal ≤7 % 8 % individual age 60 year old ; aspirin 100 mg/day clopidogrel 75 mg/day ; anti-ischemic therapy require ( propranolol isosorbide dinitrate , alone combination ) .The physician involve clinical follow-up blind analysis perform study . Biochemical analysis Blood plasma sample assess follow : blood glucose ( Glucose GOD-PAP , Roche Diagnostics , Mannheim , Germany ) , total cholesterol ( CHOD-PAP , Roche Diagnostics , Mannheim , Germany ) , triglyceride ( TG ) ( GPO-PAP , Roche Diagnostics , Mannheim , Germany ) , high-density lipoprotein cholesterol ( HDL-C ) ( HDL cholesterol without sample pre-treatment , Roche Diagnostics , Mannheim , Germany ) , C-reactive protein ( CRP ) ( high-sensitivity CRP , Cardiophase , Dade Behring , Marburg , Germany ) , 8-isoprostane ( EIA kit , Cayman Chemical Company , Ann Arbor , MI , USA ) , interleukin-2 ( IL-2 ) ( Fluorokine® MAP Human IL-2 Kit , R &amp; D Systems , Minneapolis , MN , USA ) , tumor necrosis factor type α ( TNF-α ) ( Fluorokine MAP Human TNF-α Kit , R &amp; D Systems ) , HbA1c ( Variant II , Bio-Rad Laboratories , Hercules , CA , USA ) . Low-density lipoprotein cholesterol ( LDL-C ) calculate Friedewald formula . Plasma insulin C-peptide concentration determine electrochemiluminescence ( Roche Diagnostics , Mannheim , USA ) imunoquimioluminescence ( Immulite 2000 , Diagnostic Products Corporation , Los Angeles , CA , USA ) , respectively . The Homeostasis Model Assessment version 2 ( HOMA2 ) use estimate β-cell function ( HOMA2 % β ) insulin sensitivity ( HOMA2 % S ) . We use fast plasma insulin level compute HOMA2 % S , plasma C-peptide compute HOMA2 % β . To evaluate nitric oxide ( NO ) production , plasma level nitrite nitrate ( NOx ) measure NO chemiluminescence analyzer ( model NOA , Sievers Instruments , Boulder , CO ) reduction acidic vanadium ( III ) chloride . Brachial Artery Reactivity Brachial artery reactivity assess systematically 30 day ( D30 ) STEMI estimate decline endothelial function persist acute phase stress . At time measurement , patient abovementioned secondary prevention protocol least 3 week , include simvastatin start dose 20 mg/day . Brachial artery measurement perform over-night fasting vasoactive medication withdraw 24 hour assessment . After 10 minute rest quiet room temperature control around 22°C , brachial artery locate elbow , longitudinal image 6 8 cm take rest scan . A blood pressure cuff place forearm inflate 50 mm Hg systolic blood pressure 5 min . The cuff deflate , flow-mediated dilation ( FMD ) scan obtain two minute . Ten minute later , baseline measurement repeat five mg isosorbide dinitrate . The percentage change diameter FMD nitrate-mediated dilation calculate relation respective baseline scan . Brachial artery reactivity analyze experienced physician blind patient ' data . The intra-observer reproducibility 95 % . Echocardiography All echocardiographic measurement perform accord American Society Echocardiography European Association Echocardiography recommendation . All subject undergo complete 2D ECHO use standard ultrasound equipment ( iE 33 system , 2-5MHz sector transducer ; Philips Medical Systems , Andover , MA ) , D30 . Images acquire simultaneous electrocardiographic ( ECG ) monitoring . Images store DICOM ( Digital Imaging Communication Medicine ) measurements `` offline '' . Quantifications perform average three measurement . For ventricular remodel evaluation follow measure perform : LV end-diastolic diameter ( LVEDD ) , LV end-systolic diameter ( LVESD ) , LV septum diastolic thickness ( SD ) posterior wall diastolic thickness ( PD ) . Left ventricular mass ( LVM ) calculate formula Devereux formula indexed body surface area ( LVMI ) . LV wall relative thickness ( ER ) calculate use formula ( 2 x PPD ) / LVEDD ) . Left ventricle end diastolic volume ( LVEDV ) systolic volume ( LVESV ) LE ejection fraction ( LVEF ) calculate use Simpson 's method . Carotid ultrasound The intima-media thickness ( IMT ) presence carotid plaque assess use high-resolution ultrasound ( Philips , Model IE 33 , 3-9 MHz linear transducer , Philips Medical Systems , Andover , Massachusetts , USA ) accord protocols American Society Echocardiography . The measurement perform bilaterally posterior wall common carotid bulb internal carotid artery automatic edge detection program ( QLAB version 6.0 software ) . The carotid plaque define presence focal thicken least 50 % high adjacent area focal region IMT ≥ 1.5 mm . Coronary angiography Coronary angiography systematically perform enrolled patient accord standard technique . Lumen narrow &gt; 70 % consider significant stenosis . All coronary angiography classify Gensini score method . Efficacy reperfusion estimate TIMI flow grade myocardial blush grade ( MBG ) first angiogram thrombolysis percutaneous coronary intervention . All angiographic data obtain consensus two experience interventional cardiologist blind investigation data . Cardiac Magnetic Resonance Imaging ( CMRI ) CMRI perform D30 patient study supine position 1.5T scanner ( Signa CV/i , General Electric Healthcare , Milwaukee , Wisconsin ) 8-element cardiac phased-array surface receiver coil . All CMRI acquire breath-holds ECG gating . LV size function image cine steady-state free-precession ( typical TR 3.4 m ; TE 1.2 m ; temporal resolution 40-50 m ; in-plane spatial resolution 1.5-1.8 mm 1.8-2.1 mm , depend field view ) perform multiple parallel short-axis plane ( 8 mm thick without space ) three radial long-axis plane . Using previously describe sequence [ 9 ] ( repetition time , 4.8 m ; echo time , 1.3ms ; in-plane spatial resolution 1.5 X 2.0 mm 1.9 X 2.0 mm ) , late gadolinium enhancement image ( LGE ) match cine-image slice location acquire 10 15 minute intravenous gadolinium-DTPA administration ( 0.15 0.20 mmol/kg ; Magnevist , Berlex Pharmaceuticals , Wayne , NJ ) . Statistical method Categorical variable compare use chi-square test . Analysis covariance ( ANCOVA ) use assess association potential marker . Adjustments baseline level , age gender perform comparison . Assumptions ANCOVA model ( linearity , normality distribution equal variance ) check use histogram , normal probability plot residual scatter plot . Estimates cumulative event rate calculate Kaplan-Meier method comparison curve make Log rank test . For Cox multivariable regression model , proportional hazard assumption test add time-dependent interaction variable confirm valid model . A two-sided p-value 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>less 24 hour onset MI symptom STsegment elevation least 1 mm ( frontal plane ) 2 mm ( horizontal plane ) two contiguous lead myocardial necrosis , evidence increase least one value 99th percentile reference limit CKMB ( 25 U/L ) troponin I ( 0·04 ng/mL ) follow decline Cognitive impairment Patients unable attend followup Concomitant diseases shortterm survival expectancy , i.e . cancer , severe COPD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Clinical outcome</keyword>
	<keyword>Flow-mediated dilation</keyword>
	<keyword>Inflammation</keyword>
</DOC>